Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
23.07.25 | 09:38
24,660 Euro
+1,73 % +0,420
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
24,66024,68014:54
24,66024,70014:50

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.07.Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook5
16.07.Swedish Orphan Biovitrum AB: Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum226STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased...
► Artikel lesen
15.07.Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes375STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved - for the purpose of ensuring that the company can...
► Artikel lesen
02.07.Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli7
02.07.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q2 report206Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST. STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited...
► Artikel lesen
02.07.Regulatory tracker: Sobi's Gamifant gains new FDA approval in Still's disease2
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
01.07.Sobi agrees to pay up to $300M to reduce royalty payments to Apellis on Empaveli3
01.07.Apellis stock rises after $300 million royalty deal with Sobi2
01.07.Apellis signs royalty purchase deal with Sobi for Aspaveli3
01.07.Swedish Orphan Biovitrum AB: Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli (systemic pegcetacoplan)402STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty...
► Artikel lesen
01.07.Apellis Pharmaceuticals, Inc.: Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan)5
30.06.FDA approves Sobi's Gamifant to treat severe inflammatory arthritis complication3
30.06.Sobi gains FDA approval for Gamifant to treat HLH/MAS1
28.06.Swedish Orphan Biovitrum AB: FDA approves Gamifant (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease641Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28...
► Artikel lesen
20.06.Swedish Orphan Biovitrum AB: Sobi will showcase extensive research and clinical outcomes at ISTH 2025303STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH)...
► Artikel lesen
12.06.Swedish Orphan Biovitrum AB: Sobi share new clinical data across multiple hematologic diseases at EHA 2025508STOCKHOLM, June 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress...
► Artikel lesen
10.06.Sobi/Apellis' pegcetacoplan shows sustained efficacy in phase 3 kidney disease study6
10.06.Sobi shares fall following FDA approval of rival RSV vaccine2
10.06.Sobi-Aktien fallen nach FDA-Zulassung eines konkurrierenden RSV-Impfstoffs2
06.06.Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases554STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating...
► Artikel lesen
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1